285. Fanconi anemia Clinical trials / Disease details

Clinical trials : 62 / Drugs : 93 - (DrugBank : 30) / Drug target genes : 30 - Drug target pathways : 144

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03600909 (ClinicalTrials.gov)	May 15, 2018	17/7/2018	A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia	A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine	Fanconi Anemia;Myelodysplastic Syndrome (MDS);Acute Myelogenous Leukemia (AML)	Drug: Busulfan;Drug: Fludarabine;Drug: Cyclophosphamide;Drug: Anti-Thymocyte Globulin (Rabbit);Device: The CliniMACS device;Drug: G-CSF	Memorial Sloan Kettering Cancer Center	Pediatric Brain Tumor Consortium	Completed	1 Month	N/A	All	3	Phase 2	United States
2	NCT02143830 (ClinicalTrials.gov)	April 2014	28/4/2014	HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy	A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine	Fanconi Anemia;Severe Marrow Failure;Myelodysplastic Syndrome (MDS);Acute Myelogenous Leukemia (AML)	Drug: Busulfan;Drug: Cyclophosphamide;Drug: Fludarabine;Drug: rabbit ATG;Drug: G-CSF;Biological: Peripheral blood stem cell	Children's Hospital Medical Center, Cincinnati	Fred Hutchinson Cancer Center;Memorial Sloan Kettering Cancer Center	Recruiting	3 Months	N/A	All	70	Phase 2	United States
3	NCT01082133 (ClinicalTrials.gov)	October 2009	5/3/2010	Multicenter Transplant Study for Fanconi Anemia	A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine	Fanconi Anemia	Drug: Chemotherapy;Biological: Miltenyi CliniMACS	Children's Hospital Medical Center, Cincinnati	NULL	Completed	N/A	N/A	Both	45	Phase 2	United States
4	NCT00987480 (ClinicalTrials.gov)	September 25, 2009	30/9/2009	Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine	A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine	Aplastic Anemia;Leukemia;Myelodysplastic Syndrome	Drug: Busulfan , fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.;Device: CliniMACS device	Memorial Sloan Kettering Cancer Center	Boston Children's Hospital;Children's Hospital Medical Center, Cincinnati;Children's Hospital and Health System Foundation, Wisconsin;Rockefeller University;Fred Hutchinson Cancer Research Center	Completed	N/A	N/A	All	45	Phase 2	United States
5	NCT01071239 (ClinicalTrials.gov)	April 2009	20/5/2009	Hematopoietic Stem Cell Transplant for Fanconi Anemia	A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine	Fanconi Anemia	Device: CliniMACs device;Drug: Busulfan;Drug: Fludarabine;Drug: Cyclophosphamide;Drug: ATG	Medical College of Wisconsin	Memorial Sloan Kettering Cancer Center	Completed	N/A	N/A	All	1	Phase 2	United States